Biocon and Mylan Herceptin biosimilar stalled in EU over plant issues
admin 10th July 2017 Uncategorised 0Mylan and Biocon, which had expected to be first to market with a Herceptin biosimilar in Europe, have hit a stumbling block that could delay their bid and give Roche some breathing room before copies take a bite out of the $2 billion in sales the drug generates in Europe.
More: Biocon and Mylan Herceptin biosimilar stalled in EU over plant issues
Source: fierce